Wildtype
40Mixed / Improving· ProvisionalProduces FDA-cleared cultivated coho salmon by growing Pacific salmon cells in bioreactors that mimic wild fish physiology, targeting restaurant markets as the first approved cultivated seafood in the US.
Why it's on ClimateTicker
Wildtype's cultivated coho salmon has genuine mitigation potential by eliminating wild-catch overfishing pressure and avoiding the pollution, escapee risks, and antibiotic use of conventional aquaculture. However, the environmental case rests on unverified assumptions about bioreactor energy intensity at commercial scale — published LCA research flags that energy use for bioreactor operation and cooling could make cultivated seafood more carbon-intensive than conventional farmed fish unless powered by renewables. Until Wildtype publishes an independent, peer-reviewed LCA for its own process, the climate thesis is plausible but not proven.
Controversy & Greenwashing Watch
Wildtype markets its product as environmentally superior to conventional salmon but has published no independent lifecycle assessment; sector research warns bioreactor energy intensity could exceed conventional aquaculture emissions at commercial scale without clean energy sourcing.source ↗
Cultivated meat and seafood investment fell 75% in 2023 and another 40% in 2024 to just $139M industry-wide, with Wildtype's most recent major raise being a $100M Series B in 2022, raising questions about runway and scale-up viability.source ↗
Seven US states have enacted bans on cultivated meat sales, forcing Wildtype to exit or avoid those markets and join litigation challenging the laws as unconstitutional — creating significant regulatory and commercial uncertainty.source ↗
Community Reviews
No reviews yet. Be the first to share your experience!